Molecular diagnosis of the myeloproliferative neoplasms: UK guidelines for the detection of JAK2 V617F and other relevant mutations (Q43979129)

28 November 2017

Molecular diagnosis of the myeloproliferative neoplasms: UK guidelines for the detection of JAK2 V617F and other relevant mutations (English)

1 reference

28 November 2017

19

1 reference

British Committee for Standards in Haematology

28 November 2017

Gareth Gerrard

5

0 references

20

object named as

British Committee for Standards in Haematology

1 reference

28 November 2017

Anthony J Bench

1

1 reference

28 November 2017

Helen E White

2

1 reference

28 November 2017

Letizia Foroni

3

1 reference

28 November 2017

Anna L Godfrey

4

1 reference

28 November 2017

Susanna Akiki

6

1 reference

28 November 2017

Abida Awan

7

1 reference

28 November 2017

Ian Carter

8

1 reference

28 November 2017

Andrea Goday-Fernandez

9

1 reference

28 November 2017

Stephen E Langabeer

10

1 reference

28 November 2017

Tim Clench

11

1 reference

28 November 2017

Jordan Clark

12

1 reference

28 November 2017

Paul A Evans

13

1 reference

28 November 2017

David Grimwade

14

1 reference

28 November 2017

Anna Schuh

15

1 reference

28 November 2017

Mary F McMullin

16

1 reference

28 November 2017

Anthony R Green

17

1 reference

28 November 2017

Claire N Harrison

18

1 reference

28 November 2017

language of work or name

English

0 references

publication date

11 October 2012

1 reference

British Journal of Haematology

28 November 2017

1 reference

28 November 2017

160

1 reference

28 November 2017

1

1 reference

28 November 2017

25-34

1 reference

Hydroxyurea does not appreciably reduce JAK2 V617F allele burden in patients with polycythemia vera or essential thrombocythemia

28 November 2017

1 reference

MPL mutations in myeloproliferative disorders: analysis of the PT-1 cohort.

21 January 2018

1 reference

Clonal diversity in the myeloproliferative neoplasms: independent origins of genetically distinct clones

21 January 2018

1 reference

Clinical utility of routine MPL exon 10 analysis in the diagnosis of essential thrombocythaemia and primary myelofibrosis.

21 January 2018

1 reference

Definition of subtypes of essential thrombocythaemia and relation to polycythaemia vera based on JAK2 V617F mutation status: a prospective study.

21 January 2018

1 reference

Clinical performance of JAK2 V617F mutation detection assays in a molecular diagnostics laboratory: evaluation of screening and quantitation methods.

21 January 2018

1 reference

Somatic mutations of JAK2 exon 12 as a molecular basis of erythrocytosis

21 January 2018

1 reference

Amplification refractory mutation system, a highly sensitive and simple polymerase chain reaction assay, for the detection of JAK2 V617F mutation in chronic myeloproliferative disorders

21 January 2018

1 reference

JAK2 mutation and disease phenotype: a double L611V/V617F in cis mutation of JAK2 is associated with isolated erythrocytosis and increased activation of AKT and ERK1/2 rather than STAT5.

21 January 2018

1 reference

JAK2V617F mutation for the early diagnosis of Ph- myeloproliferative neoplasms in patients with venous thromboembolism: a meta-analysis.

21 January 2018

1 reference

A real-time polymerase chain reaction assay for rapid, sensitive, and specific quantification of the JAK2V617F mutation using a locked nucleic acid-modified oligonucleotide

21 January 2018

1 reference

Rapid real-time PCR assay for detection of MPL W515L mutation in patients with chronic myeloproliferative disorders

21 January 2018

1 reference

Frequent reduction or absence of detection of the JAK2-mutated clone in JAK2V617F-positive patients within the first years of hydroxyurea therapy

21 January 2018

1 reference

EZH2 mutational status predicts poor survival in myelofibrosis.

21 January 2018

1 reference

Guideline for investigation and management of adults and children presenting with a thrombocytosis

21 January 2018

1 reference

A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera

21 January 2018

1 reference

Detection of JAK2 V617F as a first intention diagnostic test for erythrocytosis.

21 January 2018

1 reference

JAK2 mutation 1849G>T is rare in acute leukemias but can be found in CMML, Philadelphia chromosome-negative CML, and megakaryocytic leukemia

21 January 2018

1 reference

Oncogenic derivatives of platelet-derived growth factor receptors.

21 January 2018

1 reference

Widespread occurrence of the JAK2 V617F mutation in chronic myeloproliferative disorders

21 January 2018

1 reference

Minimal molecular response in polycythemia vera patients treated with imatinib or interferon alpha

21 January 2018

1 reference

Rapid identification of JAK2 exon 12 mutations using high resolution melting analysis.

21 January 2018

1 reference

A gain-of-function mutation of JAK2 in myeloproliferative disorders

21 January 2018

1 reference

Monitoring of the JAK2-V617F mutation by highly sensitive quantitative real-time PCR after allogeneic stem cell transplantation in patients with myelofibrosis.

21 January 2018

1 reference

Detection of exon 12 Mutations in the JAK2 gene: enhanced analytical sensitivity using clamped PCR and nucleotide sequencing

21 January 2018

1 reference

Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis

21 January 2018

1 reference

The JAK2V617F activating mutation occurs in chronic myelomonocytic leukemia and acute myeloid leukemia, but not in acute lymphoblastic leukemia or chronic lymphocytic leukemia

21 January 2018

1 reference

Concordance of assays designed for the quantification of JAK2V617F: a multicenter study

21 January 2018

1 reference

Higher detection rate of JAK2 mutation using plasma.

21 January 2018

1 reference

MPL mutation profile in JAK2 mutation-negative patients with myeloproliferative disorders.

21 January 2018

1 reference

A standardized framework for the validation and verification of clinical molecular genetic tests

21 January 2018

1 reference

Amendment to the guideline for diagnosis and investigation of polycythaemia/erythrocytosis.

21 January 2018

1 reference

Germline JAK2 mutation in a family with hereditary thrombocytosis.

21 January 2018

1 reference

The JAK2 V617F somatic mutation, mortality and cancer risk in the general population

21 January 2018

1 reference

A sensitive detection method for MPLW515L or MPLW515K mutation in chronic myeloproliferative disorders with locked nucleic acid-modified probes and real-time polymerase chain reaction.

21 January 2018

1 reference

MPL515 mutations in myeloproliferative and other myeloid disorders: a study of 1182 patients

21 January 2018

1 reference

Primary myelofibrosis with or without mutant MPL: comparison of survival and clinical features involving 603 patients.

21 January 2018

1 reference

Clinical relevance of JAK2 (V617F) mutant allele burden

21 January 2018

1 reference

Molecular and clinical features of the myeloproliferative neoplasm associated with JAK2 exon 12 mutations.

21 January 2018

1 reference

The frequency of JAK2 exon 12 mutations in idiopathic erythrocytosis patients with low serum erythropoietin levels

21 January 2018

1 reference

JAK2 V617F tyrosine kinase mutation in cell lines derived from myeloproliferative disorders

21 January 2018

1 reference

High resolution melting analysis for JAK2 Exon 14 and Exon 12 mutations: a diagnostic tool for myeloproliferative neoplasms

21 January 2018

1 reference

A sensitive high-throughput method to detect activating mutations of Jak2 in peripheral-blood samples

21 January 2018

1 reference

JAK2V617F mutation status identifies subtypes of refractory anemia with ringed sideroblasts associated with marked thrombocytosis

21 January 2018

1 reference

Characterization of 35 new cases with four different MPLW515 mutations and essential thrombocytosis or primary myelofibrosis

21 January 2018

1 reference

Detection of JAK2 exon 12 mutations in 15 patients with JAK2V617F negative polycythemia vera

21 January 2018

1 reference

JAK2 exon 12 mutations in polycythemia vera and idiopathic erythrocytosis

21 January 2018

1 reference

Prevalance of JAK2 V617F and exon 12 mutations in polycythaemia vera.

21 January 2018

1 reference

Hereditary myeloproliferative disorders

21 January 2018

1 reference

Refractory anemia with ringed sideroblasts associated with marked thrombocytosis (RARS-T), another myeloproliferative condition characterized by JAK2 V617F mutation

21 January 2018

1 reference

A simple, rapid, and sensitive method for the detection of the JAK2 V617F mutation.

21 January 2018

1 reference

Myeloproliferative neoplasms: molecular pathophysiology, essential clinical understanding, and treatment strategies

21 January 2018

1 reference

Uses and abuses of JAK2 and MPL mutation tests in myeloproliferative neoplasms a paper from the 2010 William Beaumont hospital symposium on molecular pathology

21 January 2018

1 reference

Interlaboratory development and validation of a HRM method applied to the detection of JAK2 exon 12 mutations in polycythemia vera patients

21 January 2018

1 reference

Phenotypic variations and new mutations in JAK2 V617F-negative polycythemia vera, erythrocytosis, and idiopathic myelofibrosis

21 January 2018

1 reference

Development and inter-laboratory validation of unlabeled probe melting curve analysis for detection of JAK2 V617F mutation in polycythemia vera

21 January 2018

1 reference

JAK2(V617F): Prevalence in a large Chinese hospital population

21 January 2018

1 reference

Effects of heparin on polymerase chain reaction for blood white cells.

21 January 2018

1 reference

Quantitative assessment of the JAK2 V617F allele burden: equivalent levels in peripheral blood and bone marrow

21 January 2018

1 reference

Diagnostic and therapeutic management of eosinophilia-associated chronic myeloproliferative disorders

21 January 2018

1 reference

JAK2 Mutations are present in all cases of polycythemia vera

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.1111/BJH.12075

1 reference

28 November 2017

1 reference